title: A pilot open-label trial of citalopram for restless activity and aberrant motor behaviors in Alzheimer disease.
abstract: OBJECTIVE
  In a prospective, open-label pilot study in probable-Alzheimer disease (AD) outpatients, the authors investigated the efficacy of citalopram to reduce restless activity and aberrant motor behaviors.
  
  
  METHODS
  Nineteen subjects were evaluated with Neuropsychiatric Inventory subscale and total scores.
  
  
  RESULTS
  There was a significant decline in aberrant motor behaviors and overall behavior problems at 4, 8, and 12 weeks.
  
  
  CONCLUSIONS
  This study provides initial evidence that citalopram may be effective in reducing aberrant motor behaviors in AD. However, because of the potential biases of an open-label study, these findings need to be confirmed in a larger, controlled trial.
authors: Division of Cognitive Neurology, Department of Neurology, The Ohio State University, Columbus, OH 43210, USA. scharre.1@osu.edu
authors: Douglas W
authors: DW
authors: Scharre
authors: Rebecca A
authors: RA
authors: Davis
authors: Jennifer L
authors: JL
authors: Warner
authors: Shu-Ing
authors: SI
authors: Chang
authors: David Q
authors: DQ
authors: Beversdorf
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000150:complications* / Q000175:diagnosis; D015283:Citalopram / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010865:Pilot Projects; D011446:Prospective Studies; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000209:etiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index
chemical_list: D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors